NewswireToday - /newswire/ -
Monrovia, CA, United States, 2012/09/24 - Anthony J. Coyle, Vice President and Chief Scientific Officer of Centers for Therapeutic Innovation at Pfizer Will Give a Plenary Keynote Presentation at the 8th Modern Drug Discovery & Development Summit (October 24-26, 2012 in Philadelphia, PA).
Anthony J. Coyle, Vice President and Chief Scientific Officer of Centers for Therapeutic Innovation at Pfizer will give a plenary keynote presentation on “Partnering to Deliver the Promise of Precision Medicine” at the 8th Modern Drug Discovery & Development Summit taking place on October 24-26, 2012 in Philadelphia, PA
In 2010, Pfizer took decisive steps to launch the Centers for Therapeutic Innovation and, in doing so, has led the industry in innovation around early R&D models. Since then, CTI has made considerable operational progress - building a strong team, establishing four US-based sites, signing 19 academic partners, and generating an early research portfolio. CTI is focused on identifying the best science in the world, demonstrating scientific and operational excellence in progressing the portfolio, and building strategic alignment around projects with our RU and BU colleagues. In his presentation, Dr. Coyle will talk about Pfizer’s plan this year to focus on building an innovative early R&D portfolio that can help create options for the other RUs and BUs across Pfizer.
Anthony “Tony” Coyle is Vice President and Chief Scientific Officer of the Centers for Therapeutic Innovation (CTI). Tony is responsible for the CTI sites, which currently include CTI – New York City, CTI- Boston and CTI-California. Tony is supported by his leadership team, which will include the site heads of each CTI, his operations team, project management, clinical and Precision Medicine heads.
Tony brings an extensive knowledge of the full development process to Pfizer. As a former Vice President and Global Head of Respiratory, Inflammation, and Autoimmunity Research at Medimmune Biologics, a Division of AstraZeneca, Tony has succeeded in advancing a biologic portfolio from discovery to Phase Two in the areas of Lupus, Asthma and COPD. Prior to Medimmune, Tony was Director of Research and Biology at Millennium Pharmaceuticals, where he led a group responsible for the identification of novel target genes as well as for late stage lead optimization and delivery of both small molecule and biologic development candidates.
GTC's 8th Modern Drug Discovery and Development Summit features a plenary keynote session followed by five parallel tracks:
• 9th Stem Cell Research and Therapeutics Conference;
• 7th Assay and Drug Discovery Technologies Conference;
• 4th Translational Medicine Conference;
• 3rd Pharmacokinetics and Pharmacodynamics Conference;
• Biotechnology Transfer and Commercialization Conference;
For more information, please visit gtcbio.com/.